Navigation Links
Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

RICHMOND, Calif., March 29, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3.20 pm ET on Tuesday, April 5, 2011 at the 10th Annual Needham Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
4. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):